No profile data available.
InMed Pharmaceuticals Inc. (INM) is a non-energy raw materials company in the taste and scent chemical compounds industry, based in Vancouver, Canada, with about 6 full-time employees.
It reported revenue of $4.94 million for fiscal year 2025, up 7.5% from fiscal year 2024, and net income of -$8.16 million. In Q1 2026 (the quarter ended September 30, 2025) revenue was $1.12 million, down 11.4% from a year before. Its market capitalization was $7.47 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2025; market data as of October 9, 2026.
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream.
InMed Pharmaceuticals reported $4.94 million in revenue for fiscal year 2025, up 7.5% from $4.60 million in fiscal year 2024. In Q1 2026 revenue was $1.12 million.
$7.47 million as of October 9, 2026.
Listed companies of a similar size in the same industry (taste and scent chemical compounds) include Zivo Bioscience, Inc. (ZIVO), Bon Natural Life Limited (BON), EvoNext Holdings SA (ELVAF), Sirona Biochem Corp. (SRBCF).